MedTrace Logo

COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability

NCT05584189 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2023-06-02

Study results available
· View outcomes & findings →

Summary

SARS-CoV-2 rapid antigen over the counter usability study.

Conditions

Interventions

DEVICE

Rapid SARS-CoV-2 Antigen Test

Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person.

Sponsors & Collaborators

  • New Day Diagnostics

    collaborator NETWORK

  • MP Biomedicals, LLC

    lead INDUSTRY

Principal Investigators

  • Jason Liggett, PhD · New Day Diagnostics

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-07
Primary Completion
2021-10-27
Completion
2021-10-27
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05584189 on ClinicalTrials.gov